ArticleJournal of the Pediatric Infectious Diseases Society2022
Progressive, Long-Term Hearing Loss in Congenital CMV Disease After Ganciclovir Therapy.
Article in Journal of the Pediatric Infectious Diseases Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- American Cochlear Implant Alliance Position Statement on Newborn Congenital Cytomegalovirus Screening.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2025Guideline
- Review
- Article
- Congenital CMV and Hearing Loss-How Does it Happen and How to Prevent it.Reviews in medical virology · 2026Review
- Long-Term Outcomes in Children With Congenital Cytomegalovirus Infection.Laryngoscope investigative otolaryngology · 2026Article
- Impact of a Statewide Hearing-Targeted Congenital Cytomegalovirus Screening Mandate: An 11-Year Interrupted Time Series Analysis.medRxiv : the preprint server for health sciences · 2025Article
- Cytomegalovirus urinary excretion in children with congenital and postnatally acquired infection.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2025Article
- Article
- Prion protein alters viral control and enhances pathology after perinatal cytomegalovirus infection.Nature communications · 2024Article
- Comprehensive Analysis of Soluble Mediator Profiles in Congenital CMV Infection Using an MCMV Model.Viruses · 2024Article
- Estimates of congenital cytomegalovirus-attributable infant mortality in high-income countries: A review.Reviews in medical virology · 2024Review
- Review
- Treatment of congenital cytomegalovirus infection.Clinical and experimental pediatrics · 2023Article
- The Audiological Follow-Up of Children with Symptomatic Congenital Cytomegalovirus Infection: An Experience in Two Italian Centers.Children (Basel, Switzerland) · 2023Article
- Article
- TORCH Congenital Syndrome Infections in Central America's Northern Triangle.Microorganisms · 2023Article
- Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundLong-term hearing outcomes among children with symptomatic congenital cytomegalovirus (CMV) disease who received 6-week ganciclovir therapy early in life are unknown.
methodsLongitudinal study of 76 children with symptomatic congenital CMV disease, born 1983-2005, who were categorized into three groups: group A treated with ganciclovir; group B untreated who had microcephaly, chorioretinitis, or sensorineural hearing loss (SNHL; ≥25 dB) diagnosed in the first month of life (congenital); and group C untreated who did not meet criteria for group B.
resultsPatients in groups A (n = 17), B (n = 27), and C (n = 32) were followed to median age of 13, 11, and 13 years, respectively. In group A, patients received ganciclovir for median of 40 (range, 11-63) days; 7 (41%) had grade 3 or 4 neutropenia. Congenital SNHL was diagnosed in 11 (65%) patients in group A, 15 (56%) in group B, and none in group C. Early-onset SNHL was diagnosed between ages ≥1-12 months in an additional 4 (24%), 6 (22%), and 8 (25%) patients in groups A, B, and C, respectively. By the end of follow-up, 12 (71%), 16 (59%), and 7 (22%) of patients in groups A, B, and C, respectively, had severe (>70 dB) SNHL in the better-hearing ear.
conclusionsIn this study, most patients with symptomatic congenital CMV disease and congenital or early-onset SNHL eventually developed hearing loss severe enough to have been potential candidates for cochlear implantation, with or without 6-week ganciclovir therapy. Understanding long-term hearing outcomes of patients treated with 6-month oral valganciclovir (current standard of care) is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.